AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 54.04 |
Market Cap | 10.04B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.2 |
PE Ratio (ttm) | -45.22 |
Forward PE | n/a |
Analyst | Buy |
Ask | 56.6 |
Volume | 3,315,564 |
Avg. Volume (20D) | 2,431,134 |
Open | 58.89 |
Previous Close | 58.51 |
Day's Range | 53.39 - 59.94 |
52-Week Range | 40.62 - 79.62 |
Beta | undefined |
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th...
Analyst Forecast
According to 17 analyst ratings, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $72, which is an increase of 32.69% from the latest price.
Next Earnings Release
Analysts project revenue of $776.55M, reflecting a 20.04% YoY growth and earnings per share of -0.07, making a -74.07% decrease YoY.
1 week ago · businesswire.com
Exact Sciences to Participate in J.P. Morgan Healthcare ConferenceMADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...
2 months ago · seekingalpha.com
Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call TranscriptExact Sciences Corporation (NASDAQ:EXAS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Erik Holznecht - Director, Investor Relations Kevin Conroy - Chairman and CE...